Contribution of pancreatic enzyme replacement therapy to survival and quality of life in patients with pancreatic exocrine insufficiency

Figure 2 Mean change from baseline in body weight[35,36] (A); improvement in clinical symptoms of pancreatic exocrine insufficiency in patients with cystic fibrosis following long-term pancreatic enzyme replacement therapy[35,36] (B). ^aP < 0.05; ^bP < 0.001; ^cP < 0.0001 vs baseline. BMI: Body mass index; PERT: Pancreatic enzyme replacement therapy; SD: Standard deviation.